

## S 2010

### CCM–CARE Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Jun 27, 2019

**Current Status:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

**Latest Action:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jun 27, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/senate-bill/2010>

### Sponsor

**Name:** Sen. Udall, Tom [D-NM]

**Party:** Democratic • **State:** NM • **Chamber:** Senate

### Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Heinrich, Martin [D-NM]	D · NM		Jun 27, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jun 27, 2019

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 3573	Identical bill	Jun 28, 2019: Referred to the Subcommittee on Health.

## **Cerebral Cavernous Malformations Clinical Awareness, Research, and Education Act of 2019 or the CCM-CARE Act**

This bill requires the National Institutes of Health (NIH) and other agencies to expand and coordinate their efforts to research cerebral cavernous malformation. (Cerebral cavernous malformation is a condition in which blood vessels in the brain and spinal cord become enlarged, which can lead to seizures, paralysis, hearing or vision loss, and bleeding in the brain.)

The NIH must (1) award grants for medical, clinical, and pharmacological research; (2) award grants to support a network of clinical research centers intended to develop a cure for the condition; and (3) convene a Cerebral Cavernous Malformations Research Consortium to develop programs for clinicians, scientists, and patients.

The Centers for Disease Control and Prevention must award grants to research entities for collecting and reporting data about cerebral cavernous malformation.

The Food and Drug Administration must accelerate the clinical trial process for cerebral cavernous malformation by supporting (1) appropriate laboratory indicators of the condition, (2) the qualification of clinical outcome measures related to quality of life, (3) investigational drug applications, and (4) expedited peer-review pathways.

### **Actions Timeline**

---

- **Jun 27, 2019:** Introduced in Senate
- **Jun 27, 2019:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.